The Schiehallion Fund appoints Dr. David Chiswell and Richard Holmes to its Board as Non-Executive Directors

– GUERNSEY, St. Peter Port –  The Schiehallion Fund Limited (LON: MNTN) today announced the appointments of David Chiswell and Richard Holmes to its Board as non-executive Directors with effect from 2 September 2021.

About Dr. David Chiswell

David Chiswell, Ph.D. has over 30 years of experience in the biotechnology industry. In 1990, Dr. Chiswell co-founded Cambridge Antibody Technology and served as its CEO from 1996 to 2002. He served as CEO of Kymab Ltd from 2015 to 2018 and before that as CEO of Nabriva Therapeutics from 2009 to 2012. He served as a director of Arakis and non-executive chairman of Sosei, Arrow Therapeutics, Daniolabs, Nabriva Therapeutics, and Kymab. Dr. Chiswell is currently chairman of Albireo Pharma Inc and, Epsilogen Ltd and a board member of Avillion Bond 2 Development 2 GP.

Dr. Chiswell is also a past chairman of the UK BioIndustry Association and his contributions to the field were recognized in 2006 when he was awarded the OBE by HM the Queen for services to the biotechnology industry.

About Richard Holmes

Richard Holmes completed a BSc in Economics at the London School of Economics and then a Masters at Warwick University. He worked in various marketing roles at Unilever in London, Paris, and Milan from 1983 to 1995. He then moved to Boots Plc where he was marketing director and launched the Boots Advantage Card and set up Boots.com. In 2007, he moved to Guernsey to join the board of Specsavers Optical Group as group marketing director. He retired from full-time work in 2018. He currently holds various non-executive positions, including Lok ‘n Store Plc, Moorfields Eye Hospital, and Citizens Advice Guernsey.

For more information: http://www.schiehallionfund.com/

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.